-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationTom Lee
Last week, the Secretary of the US Department of Health and Human Services (HHS) Xavier Becerra released a plan similar to the negotiation of China's medical insurance catalog.
The NHS supports the passage of legislation and allows the federal government to negotiate annually to reduce the prices of the most expensive prescription drugs and pass the costs on to private insurance companies
All along, the major pharmaceutical manufacturers in the United States have continued to express their regulatory actions against the government to suppress high drug prices
According to ODDO analyst estimates, Novo Nordisk, which focuses on diabetes treatment, has 14% of its total sales from Medicare Part D.
Therefore, pharmaceutical manufacturers do not need to worry too much
However, if medical insurance pricing negotiations really become a reality, analysts said that this measure may spread to the entire commercial medical insurance system, causing all pharmaceutical manufacturers to be affected
Reference source: Novo Nordisk, Roche see outsized threats from US drug pricing talks: analysts